Mounjaro®
Starting from £179.99/mo
Start journey Learn moreWhat the trial data and licensed schedule tell us about 1.7mg versus 2.4mg
The biggest misconception: staying on 1.7mg is not a valid long-term plan
The most common misreading of Wegovy's dose ladder is treating 1.7mg as a plateau, a place to settle if 2.4mg feels uncomfortable. That is not how the licensed schedule works. According to the NHS medicines information for semaglutide, the titration sequence runs from 0.25mg up through 0.5mg, 1.0mg, 1.7mg, and on to 2.4mg, with roughly four weeks at each rung. The 1.7mg step exists to make the transition to 2.4mg tolerable, not to serve as a maintenance position.
In the STEP 1 trial (68 weeks, 1,961 adults with obesity, versus placebo alongside lifestyle changes) participants on the 2.4mg maintenance dose achieved around 15% average weight reduction. The published STEP 1 paper in the New England Journal of Medicine makes clear that the 2.4mg dose is the therapeutic target; the earlier rungs are tolerability bridges. People who only ever reach 1.7mg do not reach the dose studied for that outcome.
There are legitimate clinical reasons to stay at 1.7mg for longer, persistent nausea, individual tolerability, a prescriber's assessment of overall risk. But that is a clinical decision, made with full knowledge of your situation. It is not a shortcut that delivers the same result with fewer side effects. If the question is purely "which dose produces more weight loss," the evidence answers it clearly: 2.4mg does.
Side effects: how the two doses actually compare
Gastrointestinal effects are the most discussed aspect of any dose increase on semaglutide. Moving from 1.7mg to 2.4mg is, for many people, the step where nausea, loose stools or reflux flares briefly before settling. Most of these effects are transient, they tend to peak in the days immediately after a dose change and ease within one to two weeks as the body adjusts.
What matters is that the side-effect profile is not qualitatively different between the two doses. The same categories appear: nausea, vomiting, diarrhoea, constipation, indigestion and fatigue are the common ones listed in the semaglutide summary of product characteristics (available via the electronic Medicines Compendium). The question is not whether new kinds of problems appear at 2.4mg but whether the same effects arrive with more intensity.
For a significant proportion of people, the answer is: briefly, mildly, then not at all. For others, tolerability genuinely limits how far they can go. That is precisely why Wegovy is titrated slowly and why clinical re-review before any dose change matters. Our prescribers look at your history on the current dose before any increase is confirmed, that review happens at every repeat, not just at the start. You can explore the full Wegovy overview for more on how the dose schedule is managed.
How the two doses compare: a factual summary
| Feature | Wegovy 1.7mg | Wegovy 2.4mg |
|---|---|---|
| Role in the licensed schedule | Penultimate titration step | Licensed maintenance dose |
| Average weight loss evidence | Intermediate (not the figure studied in STEP 1 | ~15% over 68 weeks (STEP 1, NEJM 2021) |
| Typical duration at this dose | ~4 weeks before escalation (or longer if clinically indicated) | Ongoing maintenance, prescriber-reviewed |
| Side-effect profile | GI-led: nausea, diarrhoea, constipation | Same categories; intensity may be briefly higher after switch |
| NICE-recommended maintenance dose | No | Yes (TA875, published 8 March 2023) |
| Licensed maximum for weight loss | No | Yes (standard pen); 7.2mg single-dose pen also now approved |
NICE's appraisal of semaglutide for weight management) TA875, specifies 2.4mg as the maintenance dose within its recommendations. Staying permanently at 1.7mg sits outside the framework NICE evaluated.
What this means when you are choosing or moving between doses
People contact us about this comparison from a few different places. Some are mid-titration and weighing whether the next increase is worth it. Others are transferring from another provider and unsure what dose evidence supports. A handful have been told 1.7mg is "good enough" and want a second opinion.
The honest answer is that the weight-loss data supports 2.4mg, and any reason to stay below that deserves a clinical conversation, not a guess. If you are finding 1.7mg difficult to tolerate and want to understand what weight loss at that dose typically looks like, that is important information for your prescriber, not a reason to quietly plateau.
The full breakdown of the Wegovy dose schedule covers each step in detail. If cost is part of your thinking, our page on Wegovy pricing in the UK sets out what is genuinely included in a legitimate private prescription. And if you want a closer look at how 1.7mg and 2.4mg compare across tolerability, evidence and clinical context, that comparison covers the key differences in one place.
Your pen arrives the next working day in an unbranded DPD parcel, the tracking link comes to your phone, and the pen itself is exactly what you would receive from any GPhC-registered pharmacy. The difference with a clinically supervised route is what happens before and after that delivery: the prescriber who read your consultation notes, and the aftercare team available seven days a week if you have questions about a dose change.
Which dose suits you is a clinical decision our prescribers make with you, not one anyone should make based on a comparison page alone. If you are ready to move to the licensed maintenance dose, you can read about what to expect from Wegovy 2.4mg and the weight loss it is associated with before you begin. Start your free consultation and a GPhC-registered prescriber will review your case the same day.
Looking to start your weight loss journey?
Take a quick eligibility quiz to explore your options and see how we can support you.